慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策*

doi:10.3969/j.issn.1672-5069.2023.06.002

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (6): 773-776.doi: 10.3969/j.issn.1672-5069.2023.06.002

慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*

杨蕊旭, 齐明华

上海市上海交通大学医学院附属新华医院消化内科(杨蕊旭);深圳市第三人民医院肝病医学部(齐明华)

收稿日期:2023-09-10 出版日期:2023-11-10 发布日期:2023-11-20
通讯作者: 齐明华,E-mail:1176241776@qq.com
作者简介:杨蕊旭,女,32岁,主治医师。研究方向:代谢相关性脂肪性肝病防治研究。E-mail: ruixu.yang@hotmail.com
基金资助:
^* 国家自然科学基金资助项目(编号:82170593);深圳市医学重点学科建设基金资助项目(编号:SZXK076);深圳市高水平医院建设专项基金资助项目(编号:XJ2022004102)

Antiviral strategy of patients with chronic hepatitis B and concomitant metabolic-dysfunction-related fatty liver diseases

Yang RuiXu, Qi Minghua

Department of Gastroenterology,Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine,Shanghai 200092,China

Received:2023-09-10 Online:2023-11-10 Published:2023-11-20

摘要/Abstract

关键词: 乙型肝炎, 代谢相关性脂肪性肝病, 抗病毒治疗

Key words: Hepatitis B, Metabolic-dysfunction-related fatty liver diseases, Antiviral therapy

杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.

Yang RuiXu, Qi Minghua. Antiviral strategy of patients with chronic hepatitis B and concomitant metabolic-dysfunction-related fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(6): 773-776.

参考文献

[1] 中华医学会肝病学分会,中华医学会感染病分会. 慢性乙型肝炎防治指南(2022年版). 实用肝脏病杂志,2023,26(3):S18-S39.
[2] 中华医学会肝病学分会.扩大慢性乙型肝炎抗病毒治疗的专家意见.中华肝脏病杂志,2022,30(2):131-136.
[3] 中华医学会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志,2018,37(1):41-45.
[4] Eslam M, Sanyal AJ, George J,et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7):1999-2014.
[5] Sarin SK,Kumar M,Eslam M,et al. Liver diseases in the Asia-Pacific region:a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol,2020,5(2):167-228.
[6] Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, ﬁbrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther,2021,54:(9):1100-1109.
[7] Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int,2017, 37(4), 542-551.
[8] Wang QX, Xue J, Shi MJ, et al. Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with chronic hepatitis B-A retrospective cohort study. Diabetes Metab Syndr Obes,2022, 15:2311-2322.
[9] Huang Y, Gan Q, Lai R, et al. Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients. Front Cell Infect Microbiol,2022,11,733348.
[10] Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol,2012,56(3):533-540.
[11] Cheng YL, Wang YJ, Kao WY, et al. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS One,2013,8(8):e72049.
[12] Yu MW, Lin CL, Liu CJ, et al. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. J Formos Med Assoc,2022, 121(8):1478-1487.
[13] Walter AJ, van de Klundert MA, Jung S. Many ways to communicate-crosstalk between the HBV-infected cell and its environment. Pathogens,2022,12(1):29.
[14] Li J, Yang HI, Yeh ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis,2021,224(2):294-302.
[15] Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. World J Gastroenterol,2021,27(26):3971-3983.
[16] Wang X, Xie Q. Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis. J Clin Transl Hepatol,2022,10(1):128-133.
[17] Mao X, Cheung KS, Peng C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis. Hepatology,2023,77(5):1735-1745.
[18] Zhou R, Yang L, Zhang B, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis. J Viral Hepat,2023,30(10):793-802.
[19] Di Mauro S, Scamporrino A, Filippello A, et al. Clinical and molecular biomarkers for diagnosis and staging of NAFLD. Int J Mol Sci,2021,22(21):11905.
[20] Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open,2019,2(10):e1912565.

慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*

Antiviral strategy of patients with chronic hepatitis B and concomitant metabolic-dysfunction-related fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	施漪雯, 范建高. 代谢相关性脂肪性肝病流行现状[J]. 实用肝脏病杂志, 2023, 26(6): 777-780.
[2]	宋涛, 徐敏, 党子龙, 孙珺珺. 恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 785-788.
[3]	高丽娟, 李永库, 董新颖, 杨艺宁, 冷雪君. 艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 789-792.
[4]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[5]	张玥, 宁玲, 李文渊, 郑晓玮, 刘洪涛, 张振华, 李磊. 血清HBsAg阳性者接受肾移植术120周预后随访报告^*[J]. 实用肝脏病杂志, 2023, 26(6): 797-800.
[6]	邹涛, 张敏, 杨凡, 王丽, 喻峰. 慢性乙型肝炎和乙型肝炎肝硬化患者PBMCs 信号转导和转录激活因子3及血清可溶性CD30分子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 855-858.
[7]	贺梅年, 赵思佳, 田智超, 何秀英, 巴正武. 超声半定量评分结合弹性成像诊断慢性乙型肝炎患者早期肝硬化临床价值分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 871-874.
[8]	盛秋菊, 窦晓光. 慢性HBV感染不同疾病状态治疗策略选择与获益评价[J]. 实用肝脏病杂志, 2023, 26(5): 609-611.
[9]	张丹, 丁洋. 慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择^*[J]. 实用肝脏病杂志, 2023, 26(5): 612-614.
[10]	彭真, 宁会彬, 李宽, 尚佳. HBeAg阳性慢性HBV 感染分期和治疗新进展[J]. 实用肝脏病杂志, 2023, 26(5): 615-617.
[11]	吴育龙, 庄见齐, 刘志成, 马侠槟. 核苷(酸)类似物治疗慢性乙型肝炎患者血清HBV pgRNA变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 622-625.
[12]	王一卓, 张崴琪, 李红. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者3年随访研究[J]. 实用肝脏病杂志, 2023, 26(5): 626-629.
[13]	郝岸华, 杜忠彩, 周林, 马磊. 慢性乙型肝炎患者肝脏硬度检测和S指数变化及评估肝纤维化程度应用价值探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 630-633.
[14]	刘爱华, 符建, 陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 634-637.
[15]	张淮, 郑明华. MAFLD高危人群的筛查和分层管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 463-465.